ライフサイエンスコーパス: loading dose

1 c adverse event rates compared with a 300-mg loading dose.

2 latelet inhibition than a 600-mg clopidogrel loading dose.

3 patients allocated AZD6140 received a 270-mg loading dose.

4 We have reported NR after a 300-mg loading dose.

5 f 1.0, 1.5, 2.0, or 2.5 mg/kg weekly with no loading dose.

6 or 4 (n=10) mg/m2/day for 14 days without a loading dose.

7 received sirolimus, 5 mg daily after a 15-mg loading dose.

8 mediately after the first 2.5-mg/kg propofol loading dose.

9 ssessed by VerifyNow 1, 2, and 4 hours after loading dose.

10 h platelet-rich plasma sampled 4 hours after loading dose.

11 t improvement only with a higher intravenous loading dose.

12 ce of initiating therapeutic regimens with a loading dose.

13 ed monthly or on a PRN basis after 3 monthly loading doses.

14 monthly or pro re nata (PRN) after 3 monthly loading doses.

15 mg or 2.0 mg monthly or PRN after 3 monthly loading doses.

16 us administration of saline or dipyridamole (loading dose, 0.142 mg/kg per min for 5 minutes followed

17 hin 8 h of injury to either tranexamic acid (loading dose 1 g over 10 min followed by infusion of 1 g

18 hin 8 h of injury to either tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8

19 ials have shown leflunomide (LEF; 20 mg/day, loading dose 100 mg x 3 days) to be effective and safe f

20 cycline (50 mg intravenously every 12 hours; loading dose 100 mg).

21 After a loading dose (100 microg/kg), morphine infusions (23-26

22 The first four patients received a loading dose (15 mg/m2) of oral sirolimus on day 1 follo

23 Telet inhibition and patient Outcomes) trial loading dose (180 mg) with a high loading dose (600 mg)

24 t on a PPI at 6 h after a 600 mg clopidogrel loading dose (23.2+/-19.5% vs 35.2+/-20.9%, p=0.02), whe

25 T474 tumors were given trastuzumab (50 mg/kg loading dose, 25 mg/kg maintenance dose, administered in

26 d pressure occurring with the first propofol loading dose; 28 patients completed the study.

27 t administered subcutaneously once per week (loading dose 320 mg followed by 160 mg weekly) or placeb

28 apatinib (1500 mg), intravenous trastuzumab (loading dose 4 mg/kg [DOSAGE ERROR CORRECTED], subsequen

29 All patients received 3 loading doses 4 weeks apart and thereafter were assessed

30 (40,000 kallikrein inhibitor units [KIU]/kg loading dose, 40,000 KIU/kg pump prime, and 10,000 KIU/k

31 zumab emtansine 3.6 mg/kg; pertuzumab 840 mg loading dose, 420 mg maintenance doses) or docetaxel, ca

32 f-administered injections of growth hormone (loading dose, 5 mg per day subcutaneously for one week,

33 ime curve 6 mg/mL x min; trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance doses) plus pertuzumab

34 mes) trial loading dose (180 mg) with a high loading dose (600 mg) of clopidogrel.

35 or standard-dose clopidogrel (no additional loading dose, 75 mg daily) for 6 months.

36 , to receive either subcutaneous adalimumab (loading dose 80 mg; biweekly dose 40 mg) or placebo, wit

37 randomly assigned to receive an intravenous loading dose (800 mg) plus 5 maintenance doses (200 mg e

38 treated with aspirin and ticlopidine (500 mg loading dose and 250 mg twice daily for 14 days).

39 (arm A) or concurrent cetuximab 400 mg/m(2) loading dose and 250 mg/m(2) per week during RT (arm B).

40 y intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clop

41 y maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6

42 ts randomized to active treatment received a loading dose and a continuous infusion of polymerized bo

43 between eras included elimination of the SRL loading dose and a reduction in TAC target trough concen

44 Both the loading dose and maintenance dose of prasugrel were supe

45 Results under loading dose and maintenance therapy regimens were nearl

46 es suggest that longer intervals between the loading dose and PCI may reduce events.

47 ), with the addition of trastuzumab (4 mg/kg loading dose and then 2 mg/kg weekly or 8 mg/kg loading

48 spital to receive either rosuvastatin (40 mg loading dose and then 20 mg daily until the earliest of

49 e randomly assigned to cetuximab 400 mg/m(2) loading dose and then 250 mg/m(2) once per week with or

50 ding dose and then 2 mg/kg weekly or 8 mg/kg loading dose and then 6 mg/kg every 3 weeks).

51 were treated with cetuximab 400 mg/m(2) as a loading dose and then weekly cetuximab 250 mg/m(2) with

52 atio using computer randomisation to receive loading doses and then 30 days of intensive antiplatelet

53 Both groups received 3 monthly loading doses and were then treated every 8 weeks (q8) w

54 received pre-treatment with prasugrel (30-mg loading dose), and 1,376 received placebo.

55 All patients received a gentamicin loading dose, and had gentamicin concentrations measured

56 mics of a 300-mg versus a 600-mg clopidogrel loading dose, and the comparative effect of eptifibatide

57 /kg in 100 mL of 0.9% saline over 4 hrs as a loading dose, and then a maintenance infusion of 50 mg/k

58 5 mg PRN group was 9.9 weeks after 3 monthly loading doses, and 93% of these patients did not require

59 ys 1 and 8 and weekly thereafter (plus an IV loading dose [ approximately 10 mg/kg] on day 1) or IV a

60 Aspirin loading dose before elective PCI improves myocardial rep

61 e the optimal timing of a 300-mg clopidogrel loading dose before percutaneous coronary intervention (

62 domly assigned to receive prasugrel (a 30-mg loading dose) before the angiography (pretreatment group

63 her with cetuximab (250 mg/m(2) weekly after loading dose; cetuximab group) or without (control group

64 id and greater platelet inhibition than high-loading-dose clopidogrel; this was sustained during the

65 A loading dose does not decrease the time to response in p

66 Optimal clopidogrel loading dose during carotid stenting has not been invest

67 al aflibercept was administered as 3 initial loading doses every 4 weeks (week 0, week 4, and week 8)

68 eatment consisted of trastuzumab (T) 4 mg/kg loading dose followed by 2 mg/kg on days 1, 8, and 15; p

69 Trastuzumab was administered as a 4 mg/kg loading dose followed by 2 mg/kg weekly for 12 weeks.

70 ast cancer patients (ie, 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly).

71 (1500 mg), intravenous trastuzumab (4 mg/kg loading dose followed by 2 mg/kg), or lapatinib (1000 mg

72 weeks plus concurrent cetuximab (400 mg/m(2) loading dose followed by 250 mg/m(2) weekly) for four cy

73 re enrolled on 3 cohorts (cohort 1, 30 mg/m2 loading dose followed by 30 mg/m2 4-hour infusion; cohor

74 Subcutaneous dupilumab (a 600 mg loading dose followed by 300 mg weekly; n = 30) or place

75 initiated a phase 1 study using a 30-minute loading dose followed by 4 hours of infusion administere

76 d to receive adalimumab, 80-mg, subcutaneous loading dose followed by 40 mg every other week or place

77 30 mg/m2 4-hour infusion; cohort 2, 40 mg/m2 loading dose followed by 40 mg/m2 4-hour infusion; and c

78 receive either placebo or pertuzumab (840-mg loading dose followed by 420 mg every 3 weeks).

79 tion ACS to 1 of 3 doses of atopaxar (400-mg loading dose followed by 50, 100, or 200 mg daily) or ma

80 cetaxel 100 mg/m(2) plus trastuzumab 8 mg/kg loading dose followed by 6 mg/kg either with bevacizumab

81 assigned oral losmapimod (7.5 mg or 15.0 mg loading dose followed by 7.5 mg twice daily) or matching

82 Administration of aspirin, 325-mg loading dose followed by 81 mg/d (n = 195) or placebo (n

83 olistin (9 million international units [MIU] loading dose followed by 9 MIU daily for normal renal fu

84 -one ratio to ticagrelor and placebo (180 mg loading dose followed by 90 mg twice a day), or to clopi

85 s were randomly assigned to receive a 30-min loading dose followed by 96-hr infusions of placebo, TAK

86 SCa (15-minute loading dose followed by [//] infusion [microgram/kg per

87 Trastuzumab was given at 4 mg/kg loading dose followed by a 2 mg/kg dose once per week du

88 dose for treatments 1 to 4, then a 30 mg/m2 loading dose followed by a 50 mg/m2 4-hour infusion).

89 mg/m(2) once per week or CTX 400 mg/m(2) as loading dose followed by CTX 250 mg/m(2) once per week c

90 omly assigned to receive clopidogrel (300-mg loading dose followed by daily dose of 75 mg; n = 441) o

91 o receive the following: a 40 mg/kg IV VRC01 loading dose followed by five 20 mg/kg IV VRC01 doses ev

92 to receive cetuximab 400 mg/m(2) intravenous loading dose followed by weekly maintenance of 250 mg/m(

93 gned in a 2:1:1 ratio to oral tolevamer 9 g (loading dose) followed by 3 g every 8 hours for 14 days,

94 bitor units [KIU] in pump prime, 2x10(6) KIU loading dose, followed by 0.5x10(6) KIU/h [n=13]).

95 irst-line treatment with trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly, or a higher 8

96 lowed by 2 mg/kg weekly, or a higher 8 mg/kg loading dose, followed by 4 mg/kg weekly.

97 2 if tolerated; group A), pertuzumab (840 mg loading dose, followed by 420 mg every 3 weeks) and tras

98 r neoadjuvant cycles of trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) plus do

99 assigned them to receive clopidogrel (300-mg loading dose, followed by 75 mg once daily) or placebo.

100 o receive CytoFab, infused as a 250-units/kg loading dose, followed by nine doses of 50 units/kg ever

101 ungin acetate given intravenously as a 70-mg loading dose, followed up by 50 mg daily along with stan

102 ared with the 300-mg (n = 1,153) clopidogrel loading dose group had significantly lower 30-day unadju

103 ]; P=0.02) in the 100-mg compared with 60-mg loading dose group.

104 om day 29 through 12 months, patients in the loading-dose group received clopidogrel, 75 mg/d, and th

105 ) once every 3 weeks plus pertuzumab (840 mg loading dose --> 420 mg) once every 3 weeks, all given i

106 m(2) once per week plus trastuzumab (8 mg/kg loading dose --> 6 mg/kg) once every 3 weeks plus pertuz

107 r prasugrel (n = 95) or ticagrelor (n = 205) loading dose had platelet reactivity assessed by VerifyN

108 treated with aspirin and clopidogrel (300 mg loading dose immediately prior to stent placement, and 7

109 g From Clopidogrel Loading Dose To Prasugrel Loading Dose In Acute Coronary Syndrome Patients study:

110 Despite the inclusion of a loading dose in the Platelet Inhibition and Patient Outc

111 ent study was to assess whether a ticagrelor loading dose is associated with a further platelet inhib

112 52) who were treated with a prasugrel 60-mg loading dose (LD) either as whole or crushed tablets.

113 5-day run-in phase with a ticagrelor 180-mg loading dose (LD) followed by a ticagrelor 90-mg twice-d

114 PD effects of ticagrelor versus clopidogrel loading dose (LD) in the peri-procedural period among tr

115 rmined in a previous study was a fludarabine loading dose (LD) of 10.5 mg/m2 followed by a continuous

116 To evaluate whether chewing a loading dose (LD) of ticagrelor, 180 mg, vs traditional

117 pen-label randomly assigned to a fulvestrant loading dose (LD) regimen followed by monthly injection

118 Adding a prasugrel loading dose (LD) to a clopidogrel LD could be desirable

119 de effective platelet inhibition 2 h after a loading dose (LD).

120 to 1 of the following 3 treatments: placebo loading dose (LD)/clopidogrel 75 mg maintenance dose (MD

121 N2O plus 0.4% halothane), low dose fentanyl (loading dose [LD] 50 micrograms kg-1, maintenance dose [

122 4, and 8, with placebo at week 2; or 420 mg loading dose [LD] at week 0 followed by 300 mg at weeks

123 o receive either clopidogrel (300- to 600-mg loading dose [LD], 75 mg/day) or ticagrelor (180-mg LD,

124 andomly assigned to receive prasugrel (60 mg loading dose [LD]/10 mg maintenance dose once daily) or

125 estored using concentrated platelets after a loading dose/maintenance therapy in a time-dependent man

126 A loading dose may decrease the time to response.

127 of aflibercept without the initial 3 monthly loading doses may be a good alternative in a select grou

128 mly assigned to receive a 300-mg clopidogrel loading dose (n = 1053) or placebo (n = 1063) 3 to 24 ho

129 (n = 249) or as needed (PRN) after 3 monthly loading doses (n = 251).

130 ntration may be achieved with an intravenous loading dose of 0.45 mg/kg followed by a continuous infu

131 PSC-833 was given intravenously with a loading dose of 1.5 mg/kg over 2 hours and a simultaneou

132 LEF was initiated with a loading dose of 100 mg daily for 3 days in 61% of patien

133 Cetuximab was delivered as a loading dose of 100 to 500 mg/m(2), followed by weekly i

134 eive levosimendan, 0.1 microg/kg/min after a loading dose of 12 microg/kg (n=15), or placebo (n=15).

135 /mL (300 microM) was calculated to require a loading dose of 1200-1400 mg over a 7-day period.

136 study patients received an initial propofol loading dose of 2.5 mg/kg and were immediately started o

137 Levosimendan was administered in a loading dose of 20 microg.kg over 10 mins followed by a

138 Patients received a loading dose of 250 mg of intravenous rhuMAb HER2, then

139 250 mg of mefloquine per week (preceded by a loading dose of 250 mg/d for 3 days) and doxycycline pla

140 Patients were followed for 1 year, with a loading dose of 3 monthly intravitreal injections, follo

141 All patients received an initial loading dose of 300 mg of rilonacept by subcutaneous inj

142 dogrel (75 mg/d for long-term treatment or a loading dose of 300 mg) before the following tests.

143 Two groups of animals received either a) a loading dose of 300 microg/kg of midazolam over 15 mins,

144 Hypothermia group received a loading dose of 4 degrees C cold saline and were cooled

145 Patients received a loading dose of 4 mg/kg intravenously, followed by a 2-m

146 voriconazole vs oral placebo; a voriconazole loading dose of 400 mg was administered twice daily for

147 very 2 weeks with regimen one and three or a loading dose of 400 mg/m(2) followed by a weekly infusio

148 ous infusion at 250 mg/m(2) after an initial loading dose of 400 mg/m(2) in week 1.

149 mg/m(2)), or cetuximab (250 mg/m(2) after a loading dose of 400 mg/m(2)) until disease progression,

150 yrimidines, were treated with cetuximab at a loading dose of 400 mg/m2 followed by 250 mg/m2 weekly.

151 50 mg/m2 days 1, 8, and 15 (after an initial loading dose of 400 mg/m2), termed TPE, repeated every 2

152 commended dose for phase II/III studies is a loading dose of 400 to 500 mg/m(2) and a maintenance wee

153 The patient received a loading dose of 5 grams of aminocaproic acid (EACA) intr

154 After a loading dose of 5 mg, patients received a daily dose of

155 Patients were treated with an oral sirolimus-loading dose of 6 mg after coronary angioplasty, followe

156 Twenty-four healthy subjects received a loading dose of 600 mg clopidogrel together with placebo

157 hours after PCI, was not superior to an oral loading dose of 600 mg of clopidogrel, administered 30 m

158 us and infusion of cangrelor or to receive a loading dose of 600 mg or 300 mg of clopidogrel.

159 Amiodarone (200 mg/d after loading dose of 600 mg/d for 10 days) was used as a cali

160 were treated with HCQ, which was given in a loading dose of 600 mg/day.

161 r one of three ALS-008176 dosing regimens: 1 loading dose of 750 mg followed by 9 maintenance doses o

162 y 9 maintenance doses of 500 mg (group 1), 1 loading dose of 750 mg followed by 9 maintenance doses o

163 ys) or trastuzumab-capecitabine (trastuzumab loading dose of 8 mg/kg followed by an infusion of 6 mg/

164 gned in a 1:1 ratio to receive adalimumab (a loading dose of 80 mg followed by a dose of 40 mg every

165 received either gavestinel at an intravenous loading dose of 800 mg followed by 200 mg every 12 h for

166 Patients received a loading dose of 840 mg pertuzumab (cycle 1) followed by

167 ients in the first cohort treated at 420 mg (loading dose of 840 mg) allowed termination of additiona

168 The CMS dosing schedule was based on a loading dose of 9 MU and a 9-MU twice-daily fractioned m

169 enous LA 450 mg plus oral prasugrel 60 mg or loading dose of aspirin 300 mg plus prasugrel 60 mg oral

170 r bare metal stent), CYP2C19 genetic status, loading dose of aspirin, dose of clopidogrel before rand

171 A single high loading dose of atorvastatin administered within 24 hour

172 ore MI induction: (1) placebo-control; (2) a loading dose of clopidogrel (600 mg); (3) a loading dose

173 A loading dose of clopidogrel before a PCI has become rela

174 rmediate risk patients treated with a 600-mg loading dose of clopidogrel before PCI, incremental clin

175 A 600-mg loading dose of clopidogrel compared with 300 mg provide

176 Our aim was to determine whether a 600-mg loading dose of clopidogrel compared with 300 mg results

177 A loading dose of clopidogrel given at least 3 hours befor

178 When a 300-mg loading dose of clopidogrel is used, little benefit is o

179 temporary anticoagulation regimens, a 600-mg loading dose of clopidogrel may safely reduce 30-day isc

180 nset of an antiplatelet effect seen with the loading dose of clopidogrel, which was used in most of t

181 n the duration of pretreatment with a 600-mg loading dose of clopidogrel.

182 Four hours after she received the loading dose of cyproheptadine, she was alert and orient

183 1:1 randomization to receive either a single loading dose of girentuximab, 50 mg (week 1), followed b

184 A 10-min loading dose of intravenous ghrelin/placebo (3 mcg kg(-1

185 Subjects were randomly assigned to receive a loading dose of intravenous LA 450 mg plus oral prasugre

186 Loading dose of LA achieves an earlier platelet inhibiti

187 Nine volunteers received a 2-mg bolus loading dose of lorazepam, coincident with the start of

188 5 of 6 dogs that were given, in addition, a loading dose of mAb 15.9D5 of 1 mg/kg on day -1, 450 cGy

189 All patients received a loading dose of morphine 30 minutes before the end of su

190 fective were treated transplacentally with a loading dose of oral amiodarone for 2 to 7 days, followe

191 as seen with and without a PPI after a 60 mg loading dose of prasugrel (69.6+/-13.5% vs 76.7+/-12.4%,

192 r the first 2 hours after the standard 60 mg loading dose of prasugrel has been described.

193 vention, a higher (100 mg) than the standard loading dose of prasugrel results in greater and more co

194 those who received placebo received a 60-mg loading dose of prasugrel.

195 The single oral loading dose of propafenone appears to be highly effecti

196 A 1.5-mg/kg loading dose of PSC was followed by a 120-hour continuou

197 Patients received a loading dose of rhuMAb HER2 (250 mg i.v.) on day 0, foll

198 k baseline, patients received a subcutaneous loading dose of rilonacept 320 mg followed by weekly sub

199 nary angiography with planned PCI to an oral loading dose of SCH 530348 (10 mg, 20 mg, or 40 mg) or m

200 ns of surgical technique, and avoidance of a loading dose of sirolimus.

201 ly assigned in a 1 to 1 fashion to receive a loading dose of study drug (prasugrel 60 mg or clopidogr

202 A loading dose of study drug was administered on cardiopul

203 effects were assessed at 24 h after the last loading dose of test compound and at 2 weeks after the l

204 sought to assess platelet inhibition after a loading dose of the currently recommended antiplatelet a

205 loading dose of clopidogrel (600 mg); (3) a loading dose of ticagrelor (180 mg); or (4) a loading do

206 oading dose of ticagrelor (180 mg); or (4) a loading dose of ticagrelor followed by an adenosine A1/A

207 A loading dose of trastuzumab 4 mg/kg was administered 1 d

208 s randomly assigned to arm A received a 4-mg loading dose of trastuzumab followed by 2 mg weekly; in

209 eir 20-mg test dose or after their 400 mg/m2 loading dose of unlabeled C225 (patients 1/3/5 and 2/4/6

210 all US patients (99.1%) received clopidogrel loading doses of 600 mg, whereas 40.5% of non-US patient

211 f custirsen 640 mg intravenously after three loading doses of 640 mg.

212 ercutaneous coronary intervention, receiving loading doses of clopidogrel (600 mg, n=13 or 900 mg, n=

213 ized to the study group received four to six loading doses of ivID, 100 mg each, over a 2-wk period t

214 Subjects were randomized 2:1 to 3 loading doses of ranibizumab then retreatment every 4 we

215 After 2 initial monthly loading doses of ranibizumab, subsequent ranibizumab was

216 electrographic seizures not responding to a loading-dose of phenobarbital from eight neonatal intens

217 located patients (1:1) to ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for

218 weekly trastuzumab intravenously at 4 mg/kg loading dose on day 1 with subsequent weekly doses of 2

219 ilable on the comparative effect of a 600-mg loading dose on the incidence of NR and high post-PA.

220 of subcutaneous denosumab every 4 weeks with loading doses on days 8 and 15 of the first cycle; those

221 /m(2), plus intravenous trastuzumab 4 mg/kg (loading dose) on day 1 and 2 mg/kg on days 1, 8, and 15

222 (2) and trastuzumab 2 mg/kg (after a 4 mg/kg loading dose) once per week for 12 weeks, while those ra

223 ), or to clopidogrel and placebo (300-600 mg loading dose or continuation with maintenance dose follo

224 eous adalimumab (40 mg every 2 weeks after a loading dose) or low-dosage oral methotrexate sodium (7.

225 d point was platelet reactivity 2 hours post loading dose (P2Y12 reactivity units [PRU] measured by t

226 After the loading doses, patients in either arm who showed signs o

227 The primary end point of the loading-dose phase (prasugrel 60 mg versus clopidogrel 6

228 to six cycles of either trastuzumab 4 mg/kg loading dose plus 2 mg/kg weekly thereafter with paclita

229 2 every 3 weeks (TP), or trastuzumab 4 mg/kg loading dose plus 2 mg/kg weekly thereafter with paclita

230 90 mg, AZD6140 180 mg, or clopidogrel 300-mg loading dose plus 75 mg once daily for up to 12 weeks.

231 tandard clopidogrel therapy (300-600 mg oral loading dose plus 75 mg oral maintenance dose) in 56 pat

232 trastuzumab (2 mg/kg per week after 4 mg/kg loading dose) plus vinorelbine.

233 including higher clopidogrel maintenance and loading doses, prasugrel, and ticagrelor, clinicians can

234 rge clot embolization in order to achieve a "loading dose" pretreatment with the drug.

235 fit for beginning therapy with a clopidogrel loading dose prior to PCI, the practical application of

236 s infusion of lorazepam, preceded by a bolus loading dose, produces a relatively constant sedative ef

237 A 600-mg clopidogrel loading dose reduces the incidence of NR and high post-P

238 rol (standard dosing) group received a 3-day loading-dose regimen.

239 At hour 2, prasugrel 100 mg over 60 mg loading dose significantly reduced high platelet reactiv

240 Seventy-seven patients received an SIR loading dose (SIR-LD) immediately posttransplantation, a

241 splantation, and 41 patients did not (SIR no loading dose [SIR-NLD]).

242 .3%) and 600-mg (10.4% vs. 7.3%) clopidogrel loading dose subgroups (p(interaction) = 0.41).

243 bevacizumab injections every 12 weeks after loading doses supplemented with as-needed top-up treatme

244 us) in combination with trastuzumab (4 mg/kg loading dose then 2 mg/kg weekly) to determine the OTR.

245 h TIA or minor stroke to clopidogrel (300 mg loading dose then 75 mg daily; 198 patients) or placebo

246 Trastuzumab (4 mg/kg loading dose, then 2 mg/kg weekly during paclitaxel then

247 with 3.6 mg/kg T-DM1 plus pertuzumab (840-mg loading dose, then 420 mg subsequently) once every 3 wee

248 T12PR24 group, receiving telaprevir (1125-mg loading dose, then 750 mg every 8 hours) for 12 weeks an

249 before study entry, plus cetuximab 400 mg/m2 loading dose, then weekly cetuximab 250 mg/m2, plus beva

250 ceived dual antiplatelet therapy as a single loading dose (ticagrelor 180 mg plus aspirin 325 mg) and

251 grel 600 mg in Transferring From Clopidogrel Loading Dose To Prasugrel Loading Dose In Acute Coronary

252 d to receive clopidogrel were given a 300-mg loading dose unless they had already been treated with c

253 ly on days 1, 8, and 15, plus three previous loading doses) until disease progression, unacceptable t

254 s greatest in the two groups that received a loading dose--viral clearance was accelerated (P</=0.05)

255 P2Y12 reactivity units 2 hours after the loading dose was 187 (153-221) and 133 (102-165) in pati

256 The average loading dose was 6.3 mg/kg body weight, and 50% of patie

257 multivariable analysis, a 600-mg clopidogrel loading dose was an independent predictor of lower rates

258 Visual acuity after the third loading dose was associated significantly with the outco

259 A loading dose was initiated by paramedics before the pati

260 Least-squares mean PRU at 2 hours post loading dose was lower with ticagrelor (27.6) versus clo

261 likely to be discontinued if a 3-day 100-mg loading dose was prescribed, patients were younger than

262 ndomization heparin and a 600-mg clopidogrel loading dose were independent predictors of reduced acut

263 Loading doses were administered immediately after the pr

264 opofol infusion rate was adjusted and repeat loading doses were administered, if needed, using a coor

265 raphic effects were maximal 0.5 hr after the loading dose, were maintained essentially constant durin

266 roups--clinical presentation and clopidogrel loading dose--were analyzed.

267 ndomization was stratified by thienopyridine loading dose, which was determined before random assignm